Research Article
Prognostic Significance of Blood Transfusion in Newly Diagnosed Multiple Myeloma Patients without Autologous Hematopoietic Stem Cell Transplantation
Table 1
Demographic and clinicopathological characteristics of MM patients before treatment.
| Characteristic | | Transfused () (%) | Nontransfused () (%) | |
| Age | ≥60 | 40 (58.8) | 60 (53.1) | 0.537 | <60 | 28 (41.2) | 53 (46.9) | Gender | Male | 38 (55.9) | 76 (67.3) | 0.153 | Female | 30 (44.1) | 37 (32.7) | Ig isotype | IgG | 40 (58.8) | 57 (50.4) | 0.208 | IgA | 18 (26.5) | 29 (25.7) | Light chain | 10 (14.7) | 21 (18.6) | Others | 0 (0) | 6 (5.3) | ISS staging | I | 5 (7.4) | 26 (23.0) | 0.006 | II | 31 (45.6) | 55 (48.7) | III | 32 (47.0) | 32 (28.3) | ECOG | 0-1 | 52 (76.5) | 101 (89.4) | 0.020 | 2–4 | 16 (23.5) | 12 (10.6) | Plt (×109/L) | ≥100 | 52 (76.5) | 104 (92.0) | 0.003 | <100 | 16 (23.5) | 9 (8.0) | Hb (g/L) | ≥100 | 6 (8.8) | 49 (43.4) | 0.000 | <100 | 62 (91.2) | 64 (56.6) | Scr (μmol/L) | ≥177 | 24 (35.3) | 15 (13.3) | 0.001 | <177 | 44 (64.7) | 98 (86.7) | Serum Alb (g/L) | ≥35 | 13 (19.1) | 36 (31.9) | 0.062 | <35 | 55 (80.9) | 77 (68.1) | Serum -MG (μmol/L) | ≥5.5 | 32 (47.0) | 32 (28.3) | 0.011 | <5.5 | 36 (53.0) | 81 (71.7) | Serum LDH (IU/L) | ≥245 | 14 (20.6) | 14 (12.4) | 0.140 | <245 | 54 (79.4) | 99 (87.6) | Serum Ca (mmol/L)
| ≥2.75 | 11 (16.2) | 10 (8.8) | 0.136 | <2.75 | 57 (83.8) | 103 (91.2) | Bortezomib | Yes | 51 (75.0) | 60 (53.1) | 0.003 | No | 17 (25.0) | 53 (46.9) | Thalidomide | Yes | 54 (79.4) | 90 (79.6) | 0.970 | No | 14 (20.6) | 23 (20.4) |
|
|
Ig: immunoglobulin; ISS: International Staging System; ECOG: Eastern Cooperative Oncology Group; Plt: platelet; Hb: hemoglobin; Scr: serum creatinine; Alb: albumin; -MG: -microglobulin; LDH: lactate dehydrogenase; Ca: calcium.
|